NCT06513949: An ongoing trial by Implicit Bioscience
This trial is ongoing. It must report results 2 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06513949 |
|---|---|
| Title | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 15, 2025 |
| Completion date | Sept. 30, 2027 |
| Required reporting date | Sept. 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |